Stay updated on Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.

Latest updates to the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a Locations section with Oregon as a study site, updating core participation details. Removed the old Oregon Locations label and the HHS Vulnerability Disclosure link; revision updated to v3.3.3.SummaryDifference0.2%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedFooter revision updated from v3.3.1 to v3.3.2; no study content or navigation changes detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision number updated from v3.2.0 to v3.3.1 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedRemoved the government funding notice about potential delays and data currency, including references to cc.nih.gov and opm.gov for status.SummaryDifference0.4%

- Check67 days agoChange DetectedNon-significant UI/layout differences are visible between the old and new screenshots, with no changes to core content such as study title, eligibility criteria, interventions, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check95 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference6%

Stay in the know with updates to Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.